Takahiro Yamauchi
Overview
Explore the profile of Takahiro Yamauchi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
217
Citations
1294
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Makishima H, Mikasa T, Isogaya K, Miyamoto T, Yamauchi T, Yokota A, et al.
Int J Hematol
. 2025 Feb;
PMID: 40016445
This phase 1/2 study investigated the association between genetic characteristics and outcomes for NS-87/CPX-351 in Japanese patients with high-risk acute myeloid leukemia. Blood samples collected from 29 patients were analyzed...
2.
Iyama S, Chi S, Idogawa M, Ikezoe T, Fukushima K, Utsu Y, et al.
Ann Hematol
. 2025 Feb;
104(1):275-284.
PMID: 39921715
Ten-eleven translocation-2 (TET2) gene mutations are observed in 12-20% of adult patients with acute myeloid leukemia (AML). The prognostic impact of TET2 mutations in patients with AML and myelodysplastic syndromes...
3.
Kodera T, Isozaki M, Kawajiri S, Yamada S, Yamauchi T, Arishima H, et al.
Cureus
. 2025 Jan;
16(12):e74950.
PMID: 39749091
Background Prior to using the exoscope, we speculated that it represented an intermediate tool between a loupe and a microscope and had concerns about its visibility of deep, fine structures....
4.
Arai H, Hosono N, Chi S, Fukushima K, Ikeda D, Iyama S, et al.
Int J Hematol
. 2024 Dec;
121(3):378-387.
PMID: 39680349
HM-SCREEN-Japan is a multicenter collaborative project in Japan to evaluate the clinical utility of a cancer genome panel in the treatment of acute myeloid leukemia (AML). The HM-SCREEN-JAPAN02 study used...
5.
Kanamori M, Tsuzuki S, Shibahara I, Saito K, Shimoda Y, Tanaka K, et al.
Neurooncol Adv
. 2024 Dec;
6(1):vdae176.
PMID: 39659832
Background: The EF-14 clinical trial demonstrated the safety and efficacy of tumor-treating fields (TTFields) for newly diagnosed glioblastoma. This study aimed to clarify the current status, safety, and efficacy of...
6.
Tsukasaki H, Fujita K, Lee S, Morishita T, Oiwa K, Negoro E, et al.
Ann Hematol
. 2024 Oct;
103(12):5549-5555.
PMID: 39453478
Despite an emphasis on the prognostic impact of serum soluble interleukin-2 receptor (sIL-2R) at diagnosis in patients with diffuse large B-cell lymphoma (DLBCL), whether the prognostic impact of elevated sIL-2R...
7.
Yamauchi T, Kikuchi M, Iizuka Y, Tsunoda M
Acta Crystallogr F Struct Biol Commun
. 2024 Oct;
80(Pt 11):294-301.
PMID: 39382846
Proliferating cell nuclear antigen (PCNA) plays a critical role in DNA replication by enhancing the activity of various proteins involved in replication. In this study, the crystal structure of ApePCNA1,...
8.
Araie H, Hosono N, Yamauchi T
Exp Hematol
. 2024 Oct;
140:104651.
PMID: 39362576
The proper uptake of drugs in liposome formulations into target cells markedly impacts therapeutic efficacy. The protein corona (PC), formed by the adsorption of serum proteins onto the liposome surface,...
9.
Ida N, Yamauchi T
Gan To Kagaku Ryoho
. 2024 Aug;
51(7):686-690.
PMID: 39191681
Antibody-drug conjugate(ADC)contain monoclonal antibodies that target-specific tumor antigens, cytotoxic payloads, and linkers. ADCs use antibodies to selectively act on tumors, making them more effective and less toxic. In Japan, 4...
10.
Ida N, Okura M, Tanaka S, Hosono N, Yamauchi T
Oncol Rep
. 2024 May;
52(1).
PMID: 38785163
Inotuzumab ozogamicin (IO), a novel therapeutic drug for relapsed or refractory acute lymphoblastic leukemia (RR)‑(ALL), is a humanized anti‑cluster of differentiation (CD) 22 monoclonal antibody conjugated with calicheamicin that causes...